AbbVie is a global biopharmaceutical company designed and committed to improving the lives of the patients it serves. It was born six years ago when it separated from Abbott Laboratories. AbbVie has redesigned the typical culture of a pharmaceutical company. It combines the inquisitive spirit of a biotech combined with the deep expertise of an innovative medicines leader.
In Australia, AbbVie is the fifth largest pharmaceutical company , and has about 320 employees dedicated to developing and delivering a consistent stream of innovative new medicines with distinct and compelling benefits to more than 31,500 patients. Science and innovation are the cornerstones of the business.
These specialist medicines cover a broad range of therapeutic areas including immunology, virology, oncology and neuroscience and treat some of the toughest health conditions in the world. AbbVie is committed to pioneering medicines where there is great unmet need and currently, in Australia & New Zealand alone the company has 22 compounds in 104 clinical trials, across more than 286 clinical trial sites.
While the medicines are highly innovative, so too is the way the company supports patients and adds value ‘beyond the pill’. The AbbVie team works collaboratively with patient groups to help patients better understand and manage their health.
In recognition of this, Patient View, an independent global survey of patient groups perceptions of pharmaceutical companies, ranked AbbVie 3rd overall in corporate reputation.
In 2018, The Reputation Institute Global Pharma RepTrak® named AbbVie the 4th most reputable pharmaceutical company in the world.